Elevated serum fibroblast growth factor 21 levels correlate with immune recovery but not mitochondrial dysfunction in HIV infection

Background

Anti-retroviral treated HIV-infected patients are at risk of mitochondrial toxicity, but non-invasive markers are lacking. Serum FGF-21 (fibroblast growth factor 21) levels correlate strongly with muscle biopsy findings in inherited mitochondrial disorders. We therefore aimed to determine whether serum FGF-21 levels correlate with muscle mitochondrial dysfunction in HIV-infected patients.

Findings

We performed a cross-sectional study of anti-retroviral treated HIV-infected subjects (aged 29 – 71 years, n?=?32). Serum FGF-21 levels were determined by quantitative ELISA. Cellular mitochondrial dysfunction was assessed by COX (cytochrome c oxidase) histochemistry of lower limb skeletal muscle biopsy. Serum FGF-21 levels were elevated in 66% of subjects. Levels correlated significantly with current CD4 lymphocyte count (p?=?0.042) and with total CD4 count gain since initiation of anti-retroviral therapy (p?=?0.016), but not with the nature or duration of past or current anti-retroviral treatment. There was no correlation between serum FGF-21 levels and severity of the muscle mitochondrial (COX) defect.

Conclusions

Serum FGF-21 levels are a poor predictor of muscle mitochondrial dysfunction in contemporary anti-retroviral treated patients. Serum FGF-21 levels are nevertheless commonly elevated, in association with the degree of immune recovery, suggesting a non-mitochondrial metabolic disturbance with potential implications for future comorbidity.